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Introduction
High-dose chemotherapy followed by autologous he-
matopoietic progenitor cell transplantation (AHPCT)
has become an established modality of treatment for
patients with refractory or high-risk non-Hodgkin’s
lymphoma (NHL) as well as a wide variety of hemato-
logic malignancies.1–3 With the advantages of a rela-
tively easy collection procedure and short duration to
engraftment, peripheral blood progenitor cells (PBPCs)
or peripheral blood stem cells (PBSCs) are now pre-
ferred over bone marrow progenitor cells as a source of
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AHPCT.4 However, successful engraftment in AHPCT
relies much on the cell dose of PBPCs.5 Clinical trials
have shown that engraftment can be accelerated by
infusion of large dose of progenitor cells.6 With respect
to a safe cell dose, a number of studies have demon-
strated that a CD34+ cell dose of 2 × 106/kg or higher
in AHPCT is associated with excellent hematopoietic
recovery.6–8
A variety of regimens have been used successfully in
NHL patients for PBPC mobilization, including he-
matopoietic growth factors with or without cyclo-
phosphamide and combinations of granulocyte-colony
stimulating factor (G-CSF) and chemotherapy used
to treat NHL.9–12 Nonetheless, the optimal timing for
PBPC harvest following mobilizing therapy remains
undetermined. Also, since the infused CD34+ cell dose
influences the outcome of engraftment,6–8 how to
maximize CD34+ cell yield has continued to be stud-
ied. Efforts have been devoted to use peripheral blood
CD34+ cell count, total white blood cell count (WBC)
or both as surrogate markers to start leukapheresis for
maximizing CD34+ cell collection.13,14 The CD34+ cell
count seems to reflect more directly the resultant
CD34+ cell yield.13,14 Other factors such as age, interval
between treatment and harvest, preceding chemother-
apy and radiotherapy, dose of chemotherapy used for
PBPC mobilization, and PB platelet count on the first
day of PBPC collection have also been reported to in-
fluence PBPC yield.13,15–17 However, some of the re-
ported results are inconsistent, especially among studies
using different mobilizing regimens.
ESHAP (etoposide/methylprednisolone/cytara-
bine/cisplatin) plus G-CSF has been shown to be
effective for mobilizing PBPCs in NHL patients.11,18
Notwithstanding, factors impacting on maximizing
PBPC collection remain to be explored. We conducted
an analysis on 20 consecutive advanced NHL patients
for whom PBPCs were harvested following ESHAP
chemotherapy and G-CSF. The correlation of the
pre-apheresis peripheral blood CD34+ cell count on
the collection day to the apheresed CD34+ cell yield
was analyzed. The predictability of factors for CD34+




The patients’ characteristics are listed in Table 1. Twenty
NHL patients were recruited between March 2003
and September 2006, underwent ESHAP chemother-
apy plus G-CSF to mobilize PBPCs and were analyzed
for factors potentially correlated to the PBPC yields.
There were 10 males and 10 females, with a median
age of 48 years (range, 19–72 years). All patients had
high-risk diseases that warranted high-dose chemo-
therapy rescued by AHPCT. Before PBPC mobiliza-
tion, all patients had received chemotherapy of 4 or
more cycles (range, 4–7 cycles) of CHOP (cyclophos-
phamide, adriamycin, vincristine, prednisolone), but
still had residual tumor. One patient had received 6
additional cycles of high-dose methotrexate for brain
lymphoma and 2 other patients had received 1–3 addi-
tional cycles of ESHAP chemotherapy in addition to
the mobilizing ESHAP chemotherapy.
All the patients were treated in Taipei Veterans
General Hospital. The study was conducted in accor-
dance with the institutional regulations and informed
consent was obtained from each patient before enrol-
ment in the study.
Mobilization, leukapheresis and storage
The mobilizing method and timing of leukapheresis
have been described previously.18 Intravenous ESHAP
(methylprednisolone 500 mg/day on days 1–4, etopo-
side 40 mg/m2/day on days 1–4, cisplatin 25 mg/m2/
day continuous infusion on days 1–4, and cytosine
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WHO NHL classification (n)
Diffuse large B cell 17
Primary mediastinal B cell 3










Interval between last CT to mobilization CT (d)
Mean 29.8
Range 18–43
*Including 2 patients with bone marrow involvement and 1 with extensive
hepatic involvement. WHO = World Health Organization; NHL = non-Hodgkin’s
lymphoma; CT = chemotherapy; RT = radiotherapy.
arabinoside 2 g/m2 on day 5) was administered and
followed by 5 µg/kg/day subcutaneous injection of
G-CSF from day 7 until the day when PBPC harvest
was completed.
All 20 patients underwent daily blood cell count
examination starting from day 6, with day 1 referring
to the day when ESHAP chemotherapy was initiated.
Two consecutive daily leukaphereses were started once
peripheral blood WBC exceeded 10 × 109/L after a
nadir. Leukapheresis was conducted using the COBE
Spectra Version 6.1 cell separator (COBE BCT,
Lakewood, CO, USA). Anticoagulant citrate dextrose
solution was used to prevent clotting. Ten liters of blood
were processed for each leukapheresis. The product
obtained was mixed with DMSO (Merck, Darmstad,
Germany) in autologous plasma to a final concentra-
tion of 10%. By programmed freezing, the cells were
subsequently cryopreserved in liquid nitrogen.
Enumeration of CD34+ cells
The circulating CD34+ cell count was determined in
peripheral blood sampled in the early morning of each
leukapheresis day. Mononuclear cells were stained with
phycoerythin (PE)-conjugated anti-CD34 (anti-HPCA-
2) mouse monoclonal antibody and counterstained
with fluorescein isothiocyanate (FITC)-conjugated
anti-CD45 mouse monoclonal antibodies (Becton
Dickinson, San Jose, CA, USA). Simultest™ control
γ1/γ2a (Becton Dickinson) was used as a negative
control to quantify the non-antigen-specific antibody
binding. More than 60,000 cells were detected using
a FACS flow cytometer and analyzed with Cellquest
software (Becton Dickinson).
Statistical analysis
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Pearson’s correlation analy-
sis was applied for evaluating the relevance of pre-
leukapheresis peripheral blood CD34+ cell count and
CD34+ cell yield per leukapheresis. The Mann-Whitney
test was used to test the significance of difference
between CD34+ cell yields of cohorts with peripheral
blood CD34+ cell count ≥50×106/L and <50×106/L.
The cut-off value of peripheral blood CD34+ cell count
was set at 50 × 106/L. The mean CD34+ yield of 2
leukaphereses in the cohort with less than the cut-off
value in pre-leukspheresis peripheral blood CD34+ cells
was 1.80 × 106/kg, a value that is less than the safe
CD34+ cell dose (2.0 × 106/kg) for PBPC autograft-
ing.6–8 To evaluate other factors affecting the CD34+
cell yield per leukapheresis, a 2 × 2 crosstable with χ2
test was used. Statistical significance was considered
for all tests when p < 0.05.
Results
Leukapheresis and yield
For the 20 patients, the first day when leukapheresis
started ranged from day 12 to day 18 (median, day
15), with day 1 referring to the day when ESHAP
chemotherapy was initiated. Two leukaphereses were
performed for each patient. The mean ± standard error
of the total mononuclear cells and the total CD34+ cells
harvested for the 20 patients were 6.48 ± 3.52 × 108/
kg and 14.4 ± 16.7 × 106/kg, respectively. Fourteen
(70%) patients had their CD34+ cell yield on the first
leukapheresis day exceeding 2 × 106 cells/kg. Sixteen
patients (80%) had CD34+ cell yield of 2 leukaphere-
ses above 2 × 106/kg body weight; another 3 (15%)
between 1–2 × 106/kg and the remaining 1 (5%) below
1 × 106/kg.
Correlation of pre-leukapheresis peripheral
blood CD34+ cell count to PBPC yield
The pre-leukapheresis peripheral blood CD34+ cell
counts on the PBPC collection days were available
among 28 of the 40 leukaphereses. The mean CD34+
cells collected per leukapheresis was 6.70 ± 7.46 ×
106/kg. A significant correlation between the pre-
leukapheresis peripheral blood CD34+ cell count and
the CD34+ cell yield of each leukapheresis was shown
by a linear regression analysis (r2 = 0.870, p < 0.0001;
Figure 1A). The mean ± standard error of CD34+ cell
yield of patients with pre-leukapheresis peripheral blood
CD34+ cell count ≥ 50 × 106/L was 5.60 ± 4.32 × 106/
kg/leukapheresis, while that of patients with pre-
leukapheresis peripheral blood CD34+ cell count <50×
106/L was 0.96 ± 0.56 × 106/kg/leukapheresis (me-
dian, 0.56 × 106/kg/leukapheresis). The CD34+ yield
in the group with pre-leukapheresis peripheral blood
CD34+ cell count ≥ 50 × 106/L had a significantly
higher total CD34+ cell yield (p < 0.001; Figure 1B).
Factors affecting CD34+ cell yield
Data were analyzed to determine possible factors
affecting the CD34+ cell yield (Table 2). Patients who
experienced 6 or more courses of preceding chemo-
therapy had lower CD34+ cell yield (p=0.032). In addi-
tion, patients with > 3,500/µL of peripheral blood
WBC before mobilizing chemotherapy had better
CD34+ cell yield than those with < 3,500/µL. On the
other hand, sex, age or whether bone marrow was
involved at the initial diagnosis did not significantly
affect PBPC yield. Peripheral blood hemoglobin and
platelet count on day 1 of mobilization, chemotherapy,
severity of neutropenia and thrombocytopenia after
ESHAP, along with the time required for white cells
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to recover from nadir to number above 10 × 109/L, all
of which possibly represent marrow-reserving capacity,
did not affect PBPC yield either.
Engraftment after high-dose therapy in 
NHL patients
Sixteen of the 20 NHL patients later proceeded to
high-dose chemotherapy and AHPCT. Four patients
did not proceed to AHPCT due to disease progres-
sion shortly after PBPC harvesting (in 1 patient) or
complete remission achieved after chemotherapy (in 
2 patients) or inadequate PBPC (< 1.0 × 106/kg) har-
vested (in 1 patient). Among the 16 patients under-
going PBPC autografting, 14 had CD34+ cell dose
≥ 2.0 × 106/kg and the other 2 had CD34+ cell doses
of 1.26 and 1.60 × 106/kg, respectively. The median
time to myeloid engraftment (defined as absolute neu-
trophil count ≥ 0.5 × 109/L for 3 consecutive days) was
10 days (range, 9–11 days), while engraftment of plate-
lets (defined as platelet count ≥ 20 × 109/L for 7 con-
secutive days without transfusional support) was seen
at a median of 15 days (range, 12–18 days).
Discussion
As infused CD34+ cell dose correlates well with hema-
topoietic recovery and transplant outcome in PBPC
transplantation, adequate PBPC collection has become
a prerequisite for successful autograft. Hematopoietic
progenitor cells can be mobilized into the circulation
by G-CSF, chemotherapy or both. To maximize effi-
cient PBPC yield, the timing for PBPC collection after
these mobilizations is critical. Some criteria have been
utilized to determine when to initiate collection. Among
them, circulating peripheral blood CD34+ cell count
has been a predictor of PBPC yield mobilized with
regimens other than the ESHAP + G-CSF used in this
study.13,14,19 Using ESHAP+G-CSF, we hereby proved
that circulating peripheral blood CD34+ cell count
remains a predictor of CD34+ cell yield.
Choosing mobilizing modality has been a field of
controversy for years. The jury on the Second Interna-
tional Consensus Conference on High-Dose Therapy
with Hematopoietic Stem Cell Transplantation in
Aggressive NHL recommended that chemotherapy
plus cytokines, rather than either alone, should be used
to mobilize hematopoietic stem cells.20 Based on that
recommendation, high-dose cyclophosphamide fol-
lowed by G-CSF has been traditionally used as a mobi-
lization regimen.20 Additionally, combinations of NHL
treatment regimen and growth factors, which benefit
patients with both tumor-killing and PBPC mobiliza-
tion, were employed in increasing frequency and dem-
onstrated to be effective mobilization regimens.9,11,12,18
Some of them, including ESHAP + G-CSF, appeared
to be superior in PBPC yield.9,11,12
In this study, using ESHAP + G-CSF for NHL pa-
tients as a PBPC-mobilizing regimen, the mean CD34+
cells collected per leukapheresis was 7.2 ± 8.3 × 106/kg.
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Figure 1. The correlation between same-day pre-leukapheresis peripheral blood (PB) CD34+ cell count and CD34+ cell yield. (A) Linear
regression made by plotting CD34+ cell yield against pre-leukapheresis peripheral blood CD34+ cell count, with r2 = 0.870 and p < 0.001
calculated by variance analysis. (B) CD34+ cell yields per leukapheresis illustrated graphically in box plots with pre-leukapheresis
peripheral blood CD34+ count < 50 × 106/L and ≥ 50 × 106/L. Dots mark outliers, capped bars indicate 5th and 95th percentiles, extent
of boxes indicates 25th and 75th percentiles, and lines inside boxes indicate means. (5.60 ± 4.32 × 106/kg/leukapheresis vs.
0.96 ± 0.56 × 106/kg body weight/leukapheresis; p < 0.001, Mann-Whitney test.)
The result is comparable with those in other re-
ports.11,12,18 Among them, Lee et al reported that 
a mean of 6.0 × 106 CD34+ cells/kg/leukapheresis
was mobilized with ESHAP + G-CSF with a mean of
6 cycles of previous chemotherapy in patients with re-
lapsed or refractory lymphoma.11 A better CD34+ cell
yield was found in patients treated with ESHAP +
G-CSF than in those who underwent high-dose cyclo-
phosphamide +G-CSF.11 We confirmed that ESHAP +
G-CSF is not only an active alternative therapy for
advanced NHL but is also effective in progenitor cell
mobilization.11,21
To mobilize PBPCs with ESHAP +G-CSF in NHL
patients, one of the significant findings of this study is
that the pre-leukapheresis peripheral blood CD34+ cell
count on the day of PBPC collection reliably predicted
CD34+ cell yield. The pre-leukapheresis peripheral
blood CD34+ cell count of 50 × 106/L on the day of
PBPC collection could be regarded as a distinctly safe
threshold guaranteeing successful PBPC harvesting.
Factors influencing progenitor cell yield have been
extensively studied in numerous trials.7,13,17,22 How-
ever, it is still difficult to draw a definite conclusion
regarding these factors from these studies owing to the
heterogeneity in the patient population in terms of their
different disease characteristics. Nonetheless, there still
exists the general consensus that drugs with stem cell-
toxic properties, such as melphalan, cyclophosphamide,
carmustine, lomustine and mechlorethamine, are asso-
ciated with inferior stem cell yield.7,16,23 In our patients,
the only 2 factors with a favorable impact on the har-
vest were less than 6 preceding chemotherapy cycles
and more than 3,500/µL for pre-mobilization WBC,
which might reflect bone marrow reserve. Since the
CHOP regimen has always been the frontline treat-
ment for our patients in this study, it is unknown
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Table 2. Patient characteristics affecting CD34+ cell yield in patients with non-Hodgkin’s lymphoma
Total CD34+ cell yield






> 50 yr 1 5
≤ 50 yr 3 11
Number of previous CT cycles 0.032
< 6 1 14
≥ 6 3 2
WBC before mobilizing CT 0.013
≤ 3,500/µL 3 1
> 3,500/µL 1 15
Hb before mobilizing CT 0.549
≤ 11.0 g/dL 2 4
> 11.0 g/dL 2 12
Platelet before mobilizing CT 0.509
≤ 150,000/µL 1 2
> 150,000/µL 3 14
BM involvement at initial diagnosis 1.00
Yes 1 0
No 3 15
Nadir of ANC after ESHAP 0.509
≤ 1,000/µL 1 2
> 1,000/µL 3 14
Nadir of platelet after ESHAP 0.285
≤ 70,000/µL 1 10
> 70,000/µL 3 6
*c2 test. BW = body weight; CT = chemotherapy; WBC = white blood cell; Hb = hemoglobin; BM = bone marrow; ANC = absolute neutrophil count.
whether the aggregate effect of all the chemothera-
peutic agents or the cumulative dose of cyclophospha-
mide played the major role in impairing the CD34+
cell yield.
In conclusion, with PBPC mobilization using
ESHAP + G-CSF, pre-leukapheresis peripheral blood
CD34+ cell count ≥50×106/L on the day of collection
was a good indicator for initiating stem cell harvest-
ing. We confirmed that ESHAP +G-CSF is an efficient
mobilization regimen for NHL patients. High-dose
chemotherapy followed by AHPCT has been proven
to be superior to conventional chemotherapy in patients
with chemosensitive relapse of aggressive NHL.24 Also
patients with NHL may benefit from high-dose che-
motherapy followed by AHPCT as part of first-line
therapy.2 It is possible to decide before 6 cycles of
frontline chemotherapy whether patients with NHL
will undergo AHPCT and have PBPC harvested. From
our data, ESHAP +G-CSF is recommended for PBPC
harvesting before 6 cycles of chemotherapy with CHOP
or equivalent regimen once high-dose chemotherapy
followed by AHPCT is contemplated. However, PBPC
mobilization after 6 cycles of frontline chemotherapy
may still possibly have suboptimal quantity of CD34+
cells adequate for autograft.
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